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Highlights 
 IPT- BPD plus drug was superior to single drug after 32 weeks trial. 
 Difference persisted at 24 months follow-up for impulsivity and relationships. 
 It also persisted for perception of psychological and social functioning. 
 Differences concerning anxiety and affective instability were lost after 6 months. 
 The most of benefits of combining IPT-BPD endured two years after termination. 
 
Abstract 
 
Few investigations evaluated the long-term effects of psychotherapies in borderline 
personality disorder (BPD). In a previous study, we compared efficacy of combination of 
fluoxetine and interpersonal psychotherapy adapted to BPD (IPT-BPD) versus single 
fluoxetine administered for 32 weeks. This study is aimed to investigate whether the results 
obtained with the addition of IPT-BPD persist during a follow-up period. Forty-four patients 
who completed the 32 weeks trial underwent 24 months of follow-up receiving fluoxetine 20-
40 mg/day. Clinical Global Impression Severity (CGI-S), Hamilton Rating Scales for 
Depression and Anxiety (HDRS, HARS), Social and Occupational Functioning Assessment 
Scale (SOFAS), Satisfaction Profile (SAT-P), and Borderline Personality Disorder Severity 
Index (BPDSI) were repeated at 6, 12, and 24 months. Statistical analysis was performed with 
the general linear model. Results showed that most of the differences between combined 
therapy and single pharmacotherapy at the end of the 32 weeks trial were maintained after 24 
months follow-up. The addition of IPT-BPD to medication produced greater effects on BPD 
symptoms (impulsivity and interpersonal relationships) and quality of life (perception of 
psychological and social functioning) that endured after termination of psychotherapy. On the 
contrary, different effects on anxiety symptoms and affective instability were lost after 6 
months. 
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Interpersonal psychotherapy, combined therapy, borderline personality disorder, efficacy, 
long-term treatment, follow-up 
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1. Introduction 
Borderline personality disorder (BPD) is a severe and complex mental disorder that 
encompasses pervasive dysfunctional patterns of experience and behavior. Patients with BPD 
are characterized by instability in affects and interpersonal relationships, impulsive behavioral 
dyscontrol, transient stress-related cognitive-perceptual symptoms and low level of identity 
integration (Gunderson, 2001; Skodol, 2005; Gabbard, 2014). A common feature of BPD 
subjects is the tendency to be poorly adherent to treatments and to discontinue the therapeutic 
programme in early phases. Difficulties in obtaining patients’ compliance and relatively high 
rates of drop-out may partially explain the paucity of studies that investigate long-term 
efficacy of therapeutic interventions in this mental disorder (Gunderson, 2001; Gunderson et 
al., 2005; Bender, 2005; Gabbard, 2014). 
In accordance with the results of systematic reviews and treatment guidelines for the 
management of BPD, options to treat this disorder include both pharmacotherapy and 
psychotherapy (American Psychiatric Association, 2001; Oldham, 2005; NICE, 2009; 
NHMRC, 2012; Stoffers et al, 2012) and combination of them can be considered a valid 
approach in treating this clinical population (American Psychiatric Association, 2001; 
Oldham, 2005). Some authors suggested that psychotherapy may enhance pharmacotherapy 
effects, although it remains unclear how this treatments actually interact (Lieb et al, 2010). To 
date, psychotherapy models more extensively studied in BPD as single or combined treatment 
are: dialectical behavioral therapy (Linehan, 1993; Linehan et al., 1999, 2006; Verheul et al, 
2003), followed by mentalisation-based treatment (Bateman and Fonagy, 1999, 2008), 
transference-focused psychotherapy (Clarkin et al., 2006), cognitive therapy (Davidson et 
al.,2006), schema-focused therapy (Kellogg and Young, 2006; Giensen-Bloo et al., 2006), and 
system training for emotional predictability and problem solving (STEPPS) (Blum et al., 
2002). In recent years, interpersonal psychotherapy modified for BPD patients (IPT-BPD) 
was added to the other specific models of psychotherapy. IPT adapted for BPD was derived 
from the standard model of IPT for major depression initially developed by Klerman and 
colleagues (1984) and was designed by Markowitz (2005) to address the peculiar features of 
BPD and to deal with difficulties in interpersonal relationships experienced by these patients. 
The adaptation included noticeable changes in methods and techniques of IPT: a different 
conceptualization of the disorder was proposed (BPD was defined as a mood-inflected 
chronic illness similar to dysthymic disorder, but with sporadic outbursts of anger); length of 
treatment was prolonged (up to 34 IPT sessions over 8 months, with an acute phase of 18 IPT 
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sessions to establish a therapeutic alliance and a continuation phase of 16 sessions to develop 
more adaptive interpersonal relationships); flexibility of setting was enhanced (a 10-minute 
telephone contact once a week was provided) to handle crises and minimize the risk of 
therapeutic ruptures.  
Although several studies have established the efficacy of different psychotherapies of BPD at 
the end of short-term trials, only few investigations have evaluated the long-term effects of 
these treatments (Bateman and Fonagy, 2001, 2008; Fassbinder et al., 2007; McMain et al, 
2012). In the majority of these studies the duration of follow-up has been shorter than one 
year (Linehan et al, 1993, 1999, 2002, 2006; van den Bosh et al, 2005).  
In the case of IPT adapted to BPD no trials are available considering long-term follow-up 
either of single psychotherapy or combined therapy. Favourable data supporting the long-term 
efficacy of IPT derived from follow-up studies of IPT or therapy combining IPT and 
pharmacotherapy that were performed in other mental disorders, such as major depression of 
adolescents (Young et al, 2006,2010; Jacobsen et al, 2012; Zhou et al, 2015) and adults 
(Schramm et al, 2008; Zobel et al., 2011; Toth et al., 2013; Lemmens et al, 2015), perinatal 
depression (Brandon et al., 2012; Reay et al., 2012), dysthymia (Browne et al., 2002), and 
eating disorders (Wilfley et al., 2002; Carter et al., 2011; Hilbert et al., 2012).  
In a randomized controlled study (Bellino et al., 2010, 2015) we compared efficacy of 
combined therapy with IPT-BPD and fluoxetine (20-40 mg/day) versus single fluoxetine (20-
40 mg/day) for 32 weeks in a group of BPD patients without concomitant psychiatric 
comorbidity and we analysed clinical predictors of response to combined therapy. At the end 
of the trial, combined therapy was found significantly superior to single fluoxetine in 
decreasing severity of three symptoms of BPD (disturbance of interpersonal relationships - 
P=0.009, affective instability - P=0.02, and impulsivity - P=0.01), anxiety (HARS - 
P=0.006), and two factors of subjective quality of life (subjective perception of psychological 
functioning - P=0.003 - and social functioning - P=0.008).  
In the present study we prospectively investigate whether the differences of efficacy of 
combined therapy with IPT-BPD and fluoxetine versus single fluoxetine registered at 32 
weeks were maintained during a follow-up period of 2 years. 
 
2. Methods 
 
2.1. Procedure 
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The present study is the follow-up of a 32 weeks controlled trial, that was published in 2010 
(Bellino et al., 2010). Methods concerning design, procedures, selection and randomization of 
patients, and evaluation tools in the short-term trial were described in detail in our previous 
article. 
In the original study, 55 consecutive outpatients meeting DSM-IV-TR criteria for BPD were 
enrolled from subjects attending the Center for Personality Disorder of the Psychiatric Clinic, 
Department of Neurosciences, University of Turin, Italy, from January to December 2007. 
People with a lifetime diagnosis of delirium, dementia, amnestic disorder, or other cognitive 
disorders; schizophrenia or other psychotic disorders; bipolar disorder; and patients with a 
concomitant diagnoses of Axis I or II disorders were excluded. Patients of childbearing age 
were excluded if they were not using an adequate method of birth control, in accordance with 
the judgment of the clinician. Patients that received psychotropic drugs in the last 2 months 
and (or) psychotherapy in the last 6 months were also excluded. Diagnoses were made by an 
expert clinician and were confirmed using the Structured Clinical Interview for DSM-IV Axis 
I and II disorders (First et al., 1997a, 1997b).Written Informed consent was acquired from all 
subjects before their participation. Declaration of Helsinki guidelines were followed and the 
Ethical Committee approval was obtained. 
 
2.2. Treatment 
In the initial 32 weeks trial, patients were randomly allocated to two treatments: (1) 28 
patients received fluoxetine (20-40 mg/day) plus clinical management; (2) 27 patients 
received fluoxetine (20-40 mg/day) plus IPT-BPD. Randomization was performed using the 
web program Research Randomizer version 3.0 (Urbaniak and Plous, Social Psychology 
Network, Wesleyan University, Middletown, CT). Pharmacotherapy and psychotherapy 
started at the same time. Psychotherapy was provided by two therapists who were not the 
psychiatrist prescribing medication and who had at least 5 years of experience practicing IPT. 
The two psychotherapists treated respectively 14 and 13 subjects. Therapists in both treatment 
arms were well experienced in the management of borderline personality disorder. Sessions of 
psychotherapy were supervised twice per month by a senior psychotherapist (S.B.) checking 
for the fidelity to manual. Thirty-four sessions of IPT-BPD were provided.  
Forty-four patients who completed the 32 weeks trial (22 who received combined therapy and 
22 who received single antidepressant) underwent 24 months of follow-up. All subjects 
received single pharmacotherapy with fluoxetine (20-40 mg/day) during the follow-up period.  
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2.3 Measurement 
Clinical assessment was repeated at 6, 12, and 24 months of follow-up. This study used the 
same evaluation instruments as the original investigation: a semi-structured interview for 
clinical and demographical characteristics; the severity item of the Clinical Global Impression 
scale (CGI-S) (Guy, 1976); the Hamilton scales for depressive and anxious symptoms 
(HDRS, HARS) (Hamilton, 1959, 1960); the Social and Occupational Functioning 
Assessment Scale (SOFAS) (Goldman et al., 1992); the Satisfaction Profile (SAT-P) (Majani 
and Callegari, 1998); the Borderline Personality Disorder Severity Index (BPDSI) (Arntz et 
al., 2003). Some of these instruments (CGI-S, HDRS, HARS, SOFAS, and BPDSI) were 
administered by a single clinician with a long experience in rating scales, who was not the 
same clinician who made the diagnosis and was not involved in the treatment procedures. All 
these characteristics of the assessor were required in order to obtain a higher reliability and to 
avoid any interference between assessment and treatment. 
The CGI is a clinician-rated scale for the global assessment of illness and consists of three 
different measures: severity of illness, global improvement, and efficacy index (comparison 
between patient’s baseline condition and a ratio of current therapeutic benefit and severity of 
side effects). In this study, we considered the first scale: severity of illness. It is a 7-point 
scale that requires the clinician to rate the severity of illness at the time of assessment: (1) 
normal, (2), borderline mentally ill, (3) mildly ill, (4) moderately ill, (5) markedly ill, (6) 
severely ill, (7) extremely ill. 
The HDRS is a clinician-rated scale that scores severity of 21 depressive symptoms in the last 
week. Items are variably scored 0-2, 0-3, or 0-4, with a total score ranging from 0 to 64. 
Higher scores indicate more severe symptoms of depression. 
The HARS is a clinician-rated scale scoring severity of 14 symptoms of anxiety in the last 
week. Item are all scored 0-4, with a total score ranging from 0 to 56. Higher scores indicate 
more severe anxiety symptoms. 
The SOFAS is a clinician-rated scale to measure a patient’s impairment in social and 
occupational areas. It is independent of the psychiatric diagnosis and the severity of the 
patient’s symptoms. The score is ranged between 0 and 100. Higher scores indicate a better 
functioning. 
The SAT-P is a self-administered questionnaire that consist of 32 scales providing a 
satisfaction profile in daily life and can be considered as an indicator of subjective quality of 
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life. The SAT-P considers five different factors: “psychological functioning”; “physical 
functioning”; “work”; “sleep, food, and free time”; “social functioning”. The SAT-P asks the 
patient to evaluate his satisfaction in the last month for each of the 32 life aspects on a 10 
centimeter analogical scale ranging from “extremely dissatisfied” to “extremely satisfied”.   
The BPDSI is a semi-structured clinical interview assessing frequency and severity of BPD 
symptoms. This instrument consists of eight items scored on 10-point frequency scales 
(0=never; 10=daily), including ‘abandonment’, ‘interpersonal relationships’, ‘impulsivity’, 
‘parasuicidal behavior’, ‘affective instability’, ‘emptiness’, ‘outbursts of anger’, ‘dissociation 
and paranoid ideation’, and one item scored on a 4-point severity scale, concerning ‘identity’.  
 
2.4 Statistical analysis 
Statistical analysis was performed with the univariate general linear model to calculate the 
effects of two factors, (1) duration of follow-up and (2) type of treatment administered in the 
32 weeks trial, on each evaluation scale that had shown a significantly better improvement 
with combined therapy compared with single pharmacotherapy after 32 weeks. Analysis was 
performed on data collected at 24 months of follow-up. If at 24 months the effect of treatment 
type was no longer significant, analysis was repeated for data obtained at 6 and 12 months, in 
order to establish when the difference of effects between treatments was lost. Significance 
level was P ≤ 0.05. 
  
3. Results 
During the follow-up study, the group of 22 patients who had previously been treated with 
combined therapy received a mean ± SD dose of fluoxetine of  32.2 ± 5.3 mg/day , the group 
of 22 patients who had previously been treated with single fluoxetine received a mean ± SD 
dose of fluoxetine of 33.1 ± 6.1 mg/day. Fourteen patients of the initial group of 44 BPD 
subjects (31.8%) dropped out, 8 (18.2%) in the first 6 months of follow-up, 2 (4.6%) in the 
following 6 months, and 4 (9.1%) in the last 12 months. Of the 30 patients who completed all 
the three follow-up assessments, 14 (46.6%) subjects had received single pharmacotherapy in 
the 32 weeks original study, while 16 (53.4%) subjects had been treated with combined 
therapy. No significant difference of drop-out rate was found between the two treatment 
groups during follow-up and participants attended an average of 2.60 of three evaluations 
(SD=0.78). Forty-four patients who entered follow-up were 13 (29.5%) males and 31 (70.5%) 
females, with a mean age of 26.9±5.1. Demographic and clinical characteristics of the two 
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groups of patients at the beginning of follow-up are reported in Table 1. No significant 
differences of baseline characteristics were found between the two groups with t-test and chi-
square test. 
Statistical analysis was performed in the 30 patients who completed the 24 months of follow-
up with the univariate GLM to calculate the effects of the two factors “follow-up duration” 
and “treatment type in the 32 weeks trial”. The object was to investigate which differences 
between combined therapy and single pharmacotherapy after 32-weeks were maintained 
during the two-years follow-up.  
Similar findings were obtained with the univariate GLM for two scales: the HARS and the 
BPDSI item “affective instability”. At the end of the 32 weeks trial both duration and 
treatment type showed a significant effect on the HARS score (P<0.001 and P=0.006) and on 
the item “affective instability” (P<0.001 and P=0.02). In both cases, no significant effect was 
found at the end of the 24 months follow-up. It means that the two scales did not have further 
changes during the follow-up period and the advantage of combined therapy was not 
maintained. In order to evaluate whether the advantage of combined therapy was still present 
for the two scales after 6 and 12 months of follow up, results of the ANOVA calculated for 
these two time intervals were analysed. The effect of both duration and treatment type were 
still significant at 6 months  for the HARS (P = 0.01; P = 0.03) and for the item “affective 
instability” (P = 0.01; P = 0.03). Significant effects were lost for both duration and treatment 
type and for both HARS and “affective instability” at 12 months (HARS: P = 0.09; P = 0.07. 
“Affective instability”: P = 0.07; P = 0.08) (Tables 2 and 4). 
Different results were found with the univariate GLM for the two BPDSI items “impulsivity” 
and “interpersonal relationships” and for the two SAT-P factors “psychological functioning” 
and “social functioning”. The significant effect of treatment duration observed after 32 weeks 
of treatment (in all cases P=0.001) was lost after follow-up for all the four scales. On the 
contrary, the effect of treatment type was significant in all cases both at the end of the 32 
weeks treatment (impulsivity P=0.01, interpersonal relationships P=0.009, psychological 
functioning P=0.003, and social functioning P=0.008) and at the end of  the 24 months 
follow-up (impulsivity P<0.001, interpersonal relationships P=0.005, psychological 
functioning P=0.002, and social functioning P=0.001). It means that the two BPDSI items and 
the two SAT-P factors did not present any further change during follow-up, but the better 
results produced by combined therapy persisted. (Table 3 and 4). 
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4. Discussion 
As BPD is a chronic and lifelong disorder, one of the most important criteria for evaluating 
the efficacy of treatments is the long-term outcome. For this reason, our study is aimed to 
verify whether the benefits from the addition of interpersonal psychotherapy to 
pharmacotherapy after 32 weeks of treatment persist during a follow-up period of two years 
after termination of psychotherapy. 
Unfortunately, it is not possible to compare the results of this study with previous follow-up 
studies of combined therapy with interpersonal psychotherapy plus pharmacotherapy in BPD 
patients. To our knowledge, this is the first trial addressing this topic. 
In the original short-term study, after 32 weeks of treatment the two alternative treatments, 
fluoxetine plus IPT-BPD versus fluoxetine plus clinical management, were found both 
efficacious in BPD patients with some significant differences in favor of combined therapy. In 
particular, combination of IPT-BPD and pharmacotherapy was more efficacious than single 
pharmacotherapy in reducing severity of anxious symptoms, in improving subjective 
perception of psychological and social functioning, and in treating three BPD symptom 
domains: impulsive behavioral dyscontrol, affective instability, and interpersonal 
relationships. 
The results of the follow-up evaluation indicated that patients initially treated with combined 
therapy maintained significant advantages over controls in some BPD core symptoms and 
domains of subjective quality of life during the 24 months follow-up. In particular, the 
superior results produced by combined therapy after 32 weeks on symptoms of impulsivity 
and interpersonal relationships, and on quality of psychological and social functioning were 
still measured two years after termination of psychotherapy. On the contrary, the advantage of 
combined therapy in terms of improvement of anxiety and affective instability was not 
replicated at follow-up. More exactly, it was still significant after 6 months of follow up, but 
it was lost at the 12 months assessment. 
Considering these results, we can suggest that a psychotherapy specifically adapted for BPD 
patients, such as IPT-BPD, has a positive impact on core BPD symptoms and patients’ 
functioning that endures for a long period after its termination. In fact, IPT-BPD is a model of 
psychotherapy that is aimed to improve BPD psychopathology by a modification of 
dysfunctional interpersonal patterns. In addition, better skills to organize interpersonal 
relationships obtained with this therapy are expected to promote a more stable social 
environment and consequently a more successful control of impulsive reactions. So, 
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impulsive behavioral dyscontrol and instability in interpersonal relationships can be 
significantly affected and persistently improved a long time after concluding the 
psychotherapeutic intervention.  
Our BPD patients experienced also a long-lasting improvement of two key factors of quality 
of life, subjective perception of psychological and social functioning. This finding is 
consistent with a previous study of long-term effects of psychotherapy in patients with 
personality disorders (Antonsen et al., 2014). 
Two significant effects of type of treatment after 32 weeks, concerning severity of anxiety and 
level of affective instability, were no longer present at two-years follow-up. Both results are 
not easy to explain due to the lack of previous comparable findings. A hypothesis that can 
only be suggested for further evaluation is that the additional effects of psychotherapy on 
anxiety and affective symptoms are transient products of non-specific factors, related to the 
supportive action of therapeutic relationship, and are lost with the end of this relationship. In 
order to test this hypothesis, it would be interesting to investigate whether once-per-month 
sessions of non-specific supportive intervention during the follow-up period could succeed in 
maintaining the superior effects of combined therapy on anxiety symptoms and affective 
instability. 
The strengths of the present study are the randomized controlled design and the extended 
period of follow-up evaluation. We used both self-evaluated and clinician-rated instruments to 
obtain a more reliable assessment. Moreover, patients who completed the follow-up period 
were 68.2% of the initial sample, which can be considered an acceptable proportion. 
On the other hand, our findings are affected by some limitations. The first limit concerns the 
relatively small size of the clinical sample. A second limitation is possibly due to the 
exclusion of psychiatric comorbidities. In fact, this choice allows to avoid the effects of 
coexisting disorders on treatment response, but has the consequence that clinical 
characteristics of our patients are partly different from those found in clinical practice and can 
limit generalizability of findings. Other limits were that session adherence to IPT-BPD and 
medication compliance were not assessed.  
In conclusion, results of this study showed that a large part of the differences between 
combined therapy and single pharmacotherapy registered in BPD patients at the end of a 32 
weeks trial were maintained after 24 months of follow-up. The addition of interpersonal 
psychotherapy to the antidepressant produced greater effects on some BPD core symptoms 
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and some factors of quality of life that endured for two years after that psychotherapy 
terminated and all patients continued to receive only medication.  
Further investigations are needed to replicate these initial findings, considering the paucity of 
available data and the relevance of this topic for clinical practice. 
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Table 1. Demographic and baseline clinical characteristics of the sample of 44 BPD patients who entered the 24 
months follow-up study.  
 
 
Parameter  Pharmacotherapy 
(n=22) 
Combined therapy 
(n=22) 
Age (mean ± SD), years 26.7 ± 5.3 26.23 ± 6.4 
Gender (female), n (%) 16 (72.7%) 15 (68.2%) 
Marital status (married), n (%) 11 (50%) 14 (63.6%) 
Employment (employed), n (%) 9 (40.9%) 8 (36.4%) 
Education (mean ± SD), years 12.74 ± 4.8 12.32 ± 5.3 
Previous hospitalization, n (%) 14 (63.6%) 16 (72.7%) 
SD = standard deviation. 
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Table 2. Results of univariate GLM for anxiety symptoms measured with HARS. 
Scale Treatment Baseline (end 
of 32 weeks 
trial, T0) 
Mean ± SD 
Results of 
32 weeks 
trial  
 6 months 
(T1) 
            Mean 
± SD 
12 months   (T2) 
                   Mean 
± SD 
24 months   
(T3) 
             
Mean ± SD 
Results of 24 
months 
follow-up                                          
       
 
HARS 
 
Fluoxetine + 
Clinical 
management 
 
Fluoxetine + IPT 
 
 
9.82±1.29 
 
 
9.03±1.67 
 
T 
F=60.66 
df=2 
P< 0.001 
tr 
F=7.86 
df=1 
P=0.006 
Txtr 
F=0.14 
df=2 
P=0.87 
 
9.85±2.4 
 
 
9.68±2.8 
 
9.92 ± 2.7 
 
 
9.79 ± 3.1 
 
10.02±3.2 
 
 
9.89±3.5 
 
T 
F=56.43 
df=3 
P=0.12 
tr 
F=4.82 
df=1 
P=0.09 
Txtr  
F=0.17 
df=3 
P=0.82 
(T): time; (tr): treatment. 
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Table 3. Results of univariate GLM for factors of subjective quality of life (SAT-P). 
Factor Treatment Baseline (end 
of 32 weeks 
trial, T0) 
Mean ± SD 
Results of 
32 weeks 
trial  
 
 6 months 
(T1) 
            
Mean ± SD 
12 months   
(T2) 
                   
Mean ± SD 
24 months   
(T3) 
             
Mean ± SD 
Results of 
24 months 
follow-up                                          
      
Psychological 
functioning 
Fluoxetine + 
Clinical 
management 
 
Fluoxetine + IPT 
 
59.71±10.8 
 
 
60.31±15 
T 
F=60.59 
df=2 
P< 0.001 
tr 
F=9.17 
df=1 
P=0.003 
Txtr 
F=4.49 
df=2 
P=0.012 
60.11±10.4 
 
 
60.53±14.8 
59.31 ±10.9 
 
 
62.4 ± 13.7 
59.69±10.9 
 
 
62.81±13.5 
T 
F=57.72 
df=3 
P=0.08 
tr 
F=10.25 
df=1 
P=0.002 
Txtr 
T=3.91 
df=3 
P= 0.03 
Social 
functioning 
 
Fluoxetine + 
Clinical 
management 
 
Fluoxetine + IPT 
 
56.97±11.99 
 
 
67.35±14.59 
T 
F=11.76 
df=2 
P< 0.001 
tr 
F=5.54 
df=1 
P=0.008 
Txtr 
F=4.59 
df=2 
P=0.03 
55.60±12.4 
 
 
67.99±14.45 
56.53±12.1 
 
 
70.12±13.2 
55.32±12 
 
 
70±13.1 
T 
F=8.93 
df=3 
P=0.1 
tr 
F=7.32 
df=1 
P=0.001 
Txtr 
F=5.22 
df=3 
P=0.01 
 (T): time; (tr): treatment. 
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Table 4.  Results of univariate GLM for items of BPDSI.  
Item Treatment Baseline (end 
of 32 weeks 
trial, T0) 
Mean ± SD 
Results of 
32 weeks 
trial  
P 
 6 months 
(T1) 
            Mean 
± SD 
12 months   
(T2) 
                   
Mean ± SD 
24 months   
(T3) 
             
Mean ± SD 
Results of 
24 months 
follow-up                                          
P       
 
Interpersonal 
relationships 
 
Fluoxetine + 
Clinical 
management 
 
Fluoxetine + 
IPT 
 
 
6.97±1.30 
 
 
5.83±1.42 
 
T 
F=21.17 
df=2 
P< 0.001 
tr 
F=7.07 
df=1 
P=0.009 
Txtr 
F=7.85 
df=2 
P=0.001 
 
7.03±1.24 
 
 
5.03±1.51 
 
7.01 ±1.26 
 
 
5.45 ± 1.99 
 
7.20±1.15 
 
 
5.72±2.01 
 
T 
F=3.77 
df=3 
P=0.15 
tr 
F=8.12 
df=1 
P=0.005 
Txtr  
F=1.82 
df=3 
P= 0.42 
 
Impulsivity 
 
 
Fluoxetine + 
Clinical 
management 
 
Fluoxetine + 
IPT 
 
 
6.26±1.12 
 
 
5.23±1.11 
 
T 
F=25.37 
df=2 
P< 0.001 
tr 
F=6.78 
df=1 
P=0.01 
Txtr 
F=10.33 
df=2 
 
6.20±1.16 
 
 
5.10±1.21 
 
6.05±1.22 
 
 
4.95±1.45 
 
5.98±1.26 
 
 
4.89±1.52 
 
 
T 
F=4.61 
df=3 
P=0.1 
tr 
F=9.23 
df=1 
P<0.001 
Txtr 
F=2.54 
df=3 
21 
 
P<0.001 P=0.31 
 
Affective 
Instability 
 
Fluoxetine + 
Clinical 
management 
 
Fluoxetine + 
IPT 
 
 
6.63±0.99 
 
 
5.61±1.18 
 
T 
F=16.70 
df=2 
P< 0.001 
tr 
F=5.81 
df=1 
P=0.02 
Txtr 
F=5.07 
df=2 
P=0.007 
 
6.42±1.01 
 
 
5.96±0.90 
 
6.38±1.12 
 
 
5.99±0.88 
 
6.40±1.10 
 
 
6.06±1.22 
 
T 
F=14.75 
df=3 
P=0.09 
tr 
F=1.91 
df=1 
P=0.1 
Txtr 
F=1.09 
df=3 
P=0.2 
(T): time; (tr): treatment. 
 
 
 
 
